Thus, GPR142 agonists could potentially modify metabolism through a balanced action of gut hormones as both insulin and glucagon and is a novel therapeutic approach for treating diabetes with minimal risk for hypoglycemia which has led to the design of synthetic GPR142 agonists, which have recently reached phase 1 in clinical trials for Type 2 diabetes treatment [372,373]. Here, INS is linked to type 2 diabetes mellitus.